Loading organizations...
Aikium Inc. is a biotechnology company based in an undisclosed location that develops advanced protein therapeutics targeting undruggable proteins and intrinsically disordered regions. The organization utilizes Yotta-ML², an artificial intelligence platform combined with generative AI and mRNA display, to synthesize and evaluate a 1 trillion protein library. This proprietary technology aims to address complex medical conditions where traditional antibodies and small molecules frequently fail, specifically focusing on oncology, immune disorders, neuroinflammation, and various autoimmune diseases. Aikium currently operates out of the Bakar Labs incubator, where it became the first site to successfully synthesize this massive scale of protein libraries, and its executives have recently participated in industry forums such as the Nucleate Podcast and the PMWC Precision Medicine World Conference. The company was established in an undisclosed year by founders Eswar Iyer, Shankar Shastry, and Venkatesh Mysore.
Aikium Inc. has raised $2.0M across 1 funding round.
Aikium Inc. has raised $2.0M in total across 1 funding round.
Aikium Inc. is a pre-seed biotechnology startup founded in 2022, developing proprietary non-antibody scaffold proteins for protein therapeutics targeting challenging proteins like GPCRs in neuro-inflammation, oncology, and undruggable disordered proteins.[1][2][3] The company leverages synthetic biology, deep learning, and an AI-driven mRNA engine to design precise, programmable binding proteins, addressing data scarcity in protein interaction datasets by generating trillions of AI-optimized molecules experimentally validated against targets.[1][3] Based in Berkeley, CA, at the Bakar Bioengenuity Hub, Aikium has 5-10 employees, raised $4M via convertible note from investors like Civilization Ventures and Fellows Fund, and serves biotech partners including top cancer hospitals, demonstrating early traction with GPCR proof-of-concept successes.[1][2][3]
Aikium was founded in 2022 by Eswar Iyer (CEO, MS, PhD), Venkatesh Mysore, and Shankar Shastry, emerging from Berkeley's biotech ecosystem at 2630 Bancroft Way.[1][2][4] Iyer, highlighting the "elephant in the room" of sparse data for predicting bindings to disordered proteins, pioneered an experimental AI approach: designing binder proteins akin to antibodies, testing trillions (10^13) of precisely AI-generated molecules against targets like GPCRs, which are notoriously hard to drug.[3] Early pivotal moments include GPCR successes as proof-of-concept, leading to four partnerships—three with top cancer hospitals—validating the platform before full commercialization.[3]
Aikium rides the AI-biotech convergence trend, accelerating drug discovery for "undruggable" targets like disordered proteins and GPCRs, which comprise ~40% of human proteome but lack effective binders due to data sparsity.[3] Timing aligns with post-AlphaFold advances in protein prediction, where Aikium's experimental scale (trillions of molecules) fills critical gaps, enabling therapeutics in high-unmet-need areas like oncology and neuro-inflammation.[1][2][3] Market forces favor it: surging VC interest in synbio-AI (e.g., $4M raise), partnerships with cancer hospitals signal ecosystem validation, and Berkeley's hub positions it to influence scalable mRNA-based protein engineering, potentially expanding AI's role in personalized medicine.[1][2][3]
Aikium's momentum—early partnerships, GPCR wins, and AI experimentation—positions it for Series A scaling, likely expanding to more oncology/neuro targets and larger datasets for broader protein coverage.[3] Trends like multimodal AI models and mRNA therapeutics will amplify its edge, evolving influence from niche scaffold innovator to ecosystem enabler for undruggable drugs. Watch for clinical proof-of-concept trials, tying back to its core promise: taming proteins once deemed impossible.[1][2][3]
Aikium Inc. has raised $2.0M in total across 1 funding round.
Aikium Inc.'s investors include Fellows Fund.
Aikium Inc. has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2023 | $2M Seed | — | Fellows Fund | Announced |